SynthesisStroke2012
Renin-Angiotensin system modulators modestly reduce vascular risk in persons with prior stroke.
Synthesis in Stroke, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 31 citations in OpenAlex.
- Framework for headache management in pediatric patients with stroke and cerebrovascular lesions: A narrative review.Headache · 2026Review
- Update of the Korean Clinical Practice Guidelines for Stroke: Blood Pressure Management.Journal of clinical neurology (Seoul, Korea) · 2025Review
- Soluble (pro)renin receptor induces endothelial dysfunction and hypertension in mice with diet-induced obesity via activation of angiotensin II type 1 receptor.Clinical science (London, England : 1979) · 2021Article
- Article
- Use of antihypertensive medication after ischemic stroke in young adults and its association with long-term outcome.Annals of medicine · 2019Article
- Estimated glomerular filtration rate predicts incident stroke among Ghanaians with diabetes and hypertension.Journal of the neurological sciences · 2019Article
- The non-biphenyl-tetrazole angiotensin ATBritish journal of pharmacology · 2018Article
- Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.Pharmacological research · 2017Review
- Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor.Molecular pharmacology · 2015Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
background and purposeAlthough the efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in reducing future vascular events for patients with coronary heart disease is established, less is known about the precise benefit of these agents among patients with stroke. We evaluated whether use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers reduces future vascular events in persons with prior stroke.
methodsWe searched PubMed, Cochrane Central Register of Controlled Trials, and bibliographies of relevant trials and recent review articles to identify randomized controlled trials. Relative risk with 95% CI was used as a measure of the association between use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and risks of major vascular event (nonfatal stroke, nonfatal myocardial infarction, or death from cardiovascular causes) or stroke (ischemic or hemorrhagic) after pooling data across trials.
resultsEight randomized controlled trials with 29 667 participants were identified. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in persons with prior stroke was associated with lower risks of future major vascular events (relative risk, 0.91; 95% CI, 0.87-0.97; P=0.001; number needed to treat=71) and recurrent stroke (relative risk, 0.93; 95% CI, 0.86-0.99; P=0.03; number needed to treat=143). Heterogeneity was found among studies for end points of major vascular events (P=0.02, I(2)=61%) but not recurrent stroke (P=0.38, I(2)=6%). In subgroup analyses, there was generally no obvious heterogeneity among different study characteristics.
conclusionsTreatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker has a clear but rather modest effect on reducing vascular risk in persons with prior stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.